华兰疫苗
(301207)
| 流通市值：110.40亿 | | | 总市值：110.47亿 |
| 流通股本：6.01亿 | | | 总股本：6.01亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 44,385,271.38 | 26,775,352.59 | 1,202,505,820.54 | 805,986,896.84 |
| 营业总成本 | 113,374,875.3 | 48,488,924.09 | 1,021,513,204.01 | 757,546,402.98 |
| 其他经营收益 | | | | |
| 营业利润 | 35,417,091.51 | 40,498,849.71 | 189,775,743.48 | 139,351,616.48 |
| 利润总额 | 35,451,776.34 | 40,470,349.16 | 187,785,927.55 | 137,628,010.91 |
| 净利润 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 36,443,163.15 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,394,997,094.09 | 4,459,134,057.68 | 4,383,156,727.06 | 4,780,080,177.71 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,883,961,989.85 | 2,380,092,936.44 | 2,461,105,319.05 | 2,399,289,543.02 |
| 资产总计 | 6,278,959,083.94 | 6,839,226,994.12 | 6,844,262,046.11 | 7,179,369,720.73 |
| 流动负债: | | | | |
| 流动负债合计 | 993,389,643.14 | 1,075,676,433.66 | 1,117,018,654.74 | 1,464,360,450.82 |
| 非流动负债: | | | | |
| 非流动负债合计 | 20,836,714.9 | 21,895,258.56 | 22,953,802.22 | 40,167,626.41 |
| 负债合计 | 1,014,226,358.04 | 1,097,571,692.22 | 1,139,972,456.96 | 1,504,528,077.23 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,264,732,725.9 | 5,741,655,301.9 | 5,704,289,589.15 | 5,674,841,643.5 |
| 股东权益合计 | 5,264,732,725.9 | 5,741,655,301.9 | 5,704,289,589.15 | 5,674,841,643.5 |
| 负债和股东权益合计 | 6,278,959,083.94 | 6,839,226,994.12 | 6,844,262,046.11 | 7,179,369,720.73 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 534,783,736.44 | 268,271,989.05 | 1,300,249,759.1 | 865,490,687.86 |
| 经营活动现金流出小计 | 368,781,689.08 | 167,208,947.04 | 943,117,554.3 | 683,526,569.61 |
| 经营活动产生的现金流量净额 | 166,002,047.36 | 101,063,042.01 | 357,132,204.8 | 181,964,118.25 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 4,009,437,346.58 | 1,688,689,535 | 8,089,656,260.7 | 6,262,680,030.87 |
| 投资活动现金流出小计 | 3,731,826,863.56 | 1,769,049,054.96 | 7,909,111,927.15 | 5,773,605,406.13 |
| 投资活动产生的现金流量净额 | 277,610,483.02 | -80,359,519.96 | 180,544,333.55 | 489,074,624.74 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 0 | - | - |
| 筹资活动现金流出小计 | 432,800,026.4 | 0 | 807,893,359.75 | 440,093,339.95 |
| 筹资活动产生的现金流量净额 | -432,800,026.4 | 0 | -807,893,359.75 | -440,093,339.95 |
| 汇率变动对现金及现金等价物的影响 | -131,854.53 | -80,382.74 | 120,022.51 | 155,717.47 |
| 现金及现金等价物净增加额 | 10,680,649.45 | 20,623,139.31 | -270,096,798.89 | 231,101,120.51 |
| 期末现金及现金等价物余额 | 363,618,870.47 | 373,561,360.33 | 352,938,221.02 | 854,136,140.42 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 10,680,649.45 | - | -270,096,798.89 | - |
最新报告期：2026-08-30| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,张云逸 | 0.36 | 0.43 | 0.52 | 2026-08-30 |